Iovance Biotherapeutics Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Iovance Biotherapeutics stock.
View analyst ratings for Iovance Biotherapeutics or view top-rated stocks.

Wall Street analysts have given Iovance Biotherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Iovance Biotherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Iovance Biotherapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 21,320,000 shares, an increase of 43.3% from the March 15th total of 14,880,000 shares. Based on an average daily volume of 1,780,000 shares, the days-to-cover ratio is presently 12.0 days.
View Iovance Biotherapeutics' Short Interest.

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Iovance Biotherapeutics.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings results on Wednesday, February, 24th. The biotechnology company reported ($0.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.03.
View Iovance Biotherapeutics' earnings history.

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IOVA shares have increased by 2.0% and is now trading at $30.17.
View which stocks have been most impacted by COVID-19.

11 brokers have issued 12-month price targets for Iovance Biotherapeutics' stock. Their forecasts range from $35.00 to $65.00. On average, they anticipate Iovance Biotherapeutics' share price to reach $50.50 in the next year. This suggests a possible upside of 67.4% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Iovance Biotherapeutics include Bio-Techne (TECH), Novavax (NVAX), Novozymes A/S (NVZMY), argenx (ARGX), QIAGEN (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Twist Bioscience (TWST) and Kodiak Sciences (KOD).
View all of IOVA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Iovance Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Midwest Bank Trust Division (0.02%), Carnegie Capital Asset Management LLC (0.02%), Phoenix Wealth Advisors (0.01%) and Pacer Advisors Inc. (0.00%).
View institutional ownership trends for Iovance Biotherapeutics.

IOVA stock was sold by a variety of institutional investors in the last quarter, including Carnegie Capital Asset Management LLC, and Pacer Advisors Inc..
View insider buying and selling activity for Iovance Biotherapeutics or view top insider-selling stocks.

IOVA stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, and Phoenix Wealth Advisors.
View insider buying and selling activity for Iovance Biotherapeutics or or view top insider-buying stocks.

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IOVA stock can currently be purchased for approximately $30.17.

Iovance Biotherapeutics has a market capitalization of $4.43 billion. The biotechnology company earns $-197,560,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

Iovance Biotherapeutics employs 148 workers across the globe.

The official website for Iovance Biotherapeutics is www.iovance.com.

Iovance Biotherapeutics is headquartered at 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070.

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at (650) 260-7120 or via email at [email protected]